MYO5B and breast carcinoma: These observations led us to hypothesize that LRP5-overexpressing osteocytes inhibit breast cancer bone metastasis by engaging the LIMA1/MYO5B signaling axis, thereby disrupting tumor–stromal interactions and restoring bone–tumor homeostasis [22].